Darryn Bampton

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

Keith Dredge, Todd V. Brennan, Edward Hammond et al. · British Journal of Cancer · 2018 · 100 citations · Full text

Medicine, Oncology, Pharmacology +17

PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples

Boris Winterhoff, Luisa Freyer, Edward Hammond et al. · European Journal of Cancer · 2015 · 63 citations

Medicine, Oncology, Pharmacology +14

Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

Edward Hammond, Nicole M. Haynes, Carleen Cullinane et al. · Journal for ImmunoTherapy of Cancer · 2018 · 49 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

Charlotte Lemech, Keith Dredge, Darryn Bampton et al. · Journal for ImmunoTherapy of Cancer · 2023 · 39 citations · Full text

Medicine, Oncology, Pharmacology +17

An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors.

Keith Dredge, Todd V. Brennan, Michael P. Brown et al. · Journal of Clinical Oncology · 2017 · 10 citations

Life Sciences, Immunology, Pharmacology +15